UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~August 2612, 2022

CASI PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of

incorporation or organization)

0-20713

(Commission File Number)

58-1959440

(IRS Employer
Identification No.)

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

20850

(Zip Code)

(240) 864-2600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock		CASI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 32.0302 ~~Material~~Results ~~Modification~~of toOperations ~~Rights~~and ofFinancial ~~Security Holders~~Condition.

~~The~~On ~~information~~August ~~contained~~12, in2022, ~~Item~~CASI Pharmaceuticals, 5Inc.03 ~~below~~(the is“Company”) issued a press release reporting its financial results for the three and six month ~~incorporated~~periods byending ~~reference~~June ~~into~~30, 2022. The press release is furnished as Exhibit 99.1 to this ~~Item~~Current 3Report on Form 8-K.~~03.~~

~~Item~~The 5information on this Current Report on Form 8-K (including Exhibit 99.031) ~~Amendments~~shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”) or otherwise subject to ~~Articles~~the liabilities of ~~Incorporation~~that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or ~~Bylaws;~~the ~~Change~~Exchange Act, except as expressly set forth by specific reference in ~~Fiscal~~such ~~Year~~a filing.

OnItem ~~May 26, 2022, CASI Pharmaceuticals, Inc~~9. ~~(the “Company”) filed an amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation to effectuate a reverse stock split of the Company’s common stock, par value $.~~01 ~~per~~Financial ~~share~~Statements ~~(the “Common Stock”). Pursuant to the Amendment, at the effective time of 5:00 p.m., Eastern Time, on June 1, 2022, each ten (10) shares of Common Stock issued~~ and ~~outstanding will be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (the “Reverse Stock Split”)~~Exhibits. The par value per share of the Common Stock remains the same. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock are instead entitled to receive a proportional cash payment. The Reverse Stock Split will not reduce the total number of shares of Common Stock that the Company is authorized to issue, which will remain 250,000,000 shares. Trading of the Common Stock on a Reverse Stock Split-adjusted basis will begin at the opening of trading on the Nasdaq Capital Market on June 2, 2022. The new CUSIP number for the Common Stock following the Reverse Stock Split is 14757U 208.

In(d) addition, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of Common Stock and the number of shares of Common Stock reserved for issuance pursuant to the Company’s equity incentive plans.Exhibits

The Reverse Stock Split ratio was selected pursuant to the authority granted to the board of directors of the Company by stockholders at the Annual Meeting of Stockholders held on May 25, 2022. A copy of the Amendment filed with the Secretary of State of the State of Delaware is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Exhibit No.	Description of Document

99.1	Press Release of CASI Pharmaceuticals, Inc., dated August 12, 2022

104	Inline XBRL for the cover page of this Current Report on Form 8-K

~~Item 8.01. Other Events~~SIGNATURES

OnPursuant ~~May~~to ~~26, 2022,~~ the ~~Company~~requirements ~~issued a press release announcing the filing~~ of the ~~Amendment~~Securities Exchange ~~and~~Act ~~effective date~~ of 1934, the ~~Reverse~~registrant ~~Stock~~has ~~Split.~~duly Acaused ~~copy~~this ofreport ~~the press release is attached~~ to ~~this report~~be assigned ~~Exhibit~~on ~~99.1~~its ~~and~~behalf isby ~~incorporated~~the ~~herein~~undersigned byhereunto ~~reference~~duly authorized.

~~Item~~CASI 9PHARMACEUTICALS, INC.~~01.~~ ~~Financial~~/s/ ~~Statements~~Larry Zhang Larry (Wei) Zhang President and ~~Exhibits~~Principal Financial Officer

~~(d)~~Date: ~~Exhibits~~August 12, 2022

	Exhibit
	Number		Description
	3.1		Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation
	99.1		Press Release dated May 26, 2022
	104		Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CASI PHARMACEUTICALS, INC. (Registrant) /s/ Larry Zhang President and Principal Financial Officer

Date: May 26, 2022

Filing Compare · CASI Pharmaceuticals, Inc (DE)